Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens
Jǐnjīng Xǔ(Nanjing Medical University), Junnian Zheng(Xuzhou Medical College), Qing Zhang(South China University of Technology), Liantao Li(Jiangsu University), Hongyan Liu(Queensland University of Technology), Kang Tian(Xuzhou Medical College), Jingjie Liu(Huazhong University of Science and Technology), Haixu Zhang(Xuzhou Medical College)
Cited by 22
Related Papers
Ki67 is a promising molecular target in the diagnosis of cancer (Review)
|Molecular Medicine Reports|2014|859
Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment
|Oncotarget|2018|217
DNA damage response – A double-edged sword in cancer prevention and cancer therapy
|Cancer Letters|2014|189
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects
|Journal of Experimental & Clinical Cancer Research|2018|176
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
|Journal of Immunology Research|2018|152